BCR-ABL1 Kinase Domain Mutation Analysis [IRMA] Test
Short Name: BCR-ABL1 IRMA
Also known as: IRMA, BCR-ABL1 Mutation Analysis, Kinase Domain Mutation Test
BCR-ABL1 Kinase Domain Mutation Analysis [IRMA] Test test available at DNA Labs India for ₹11,250. Uses Sanger Sequencing on Bone marrow / Peripheral blood samples. Results in Reports are typically available within 7-8 days after the sample is received by the laboratory.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr Pasupathy Arumugam
Consultant Pathologist · Reg: 21521
Last reviewed: September 7, 2026
Overview
The primary purpose of BCR-ABL1 Kinase Domain Mutation Analysis is to identify mutations in the kinase domain of the BCR-ABL1 gene that confer resistance to tyrosine kinase inhibitors (TKIs). This information is essential for guiding treatment decisions in patients with CML or Philadelphia-positive ALL who exhibit suboptimal response or relapse. By pinpointing specific mutations, clinicians can choose the most effective TKI or consider alternative therapies such as ponatinib or allogeneic stem cell transplantation. Additionally, the test helps in monitoring disease progression and predicting prognosis. It is also used in research settings to understand resistance mechanisms. Overall, IRMA plays a pivotal role in personalized oncology, ensuring that patients receive the most appropriate and timely interventions.
- Test Code
- 6044
- CPT Code
- 81479
- ICD Code
- C92.1
- Price
- ₹11,250
- Sample Type
- Bone marrow / Peripheral blood
- Result Time
- Reports are typically available within 7-8 days after the sample is received by the laboratory.
- Fasting Required
- No
- Method
- Sanger Sequencing
Sample Collection
No special preparation is required. Inform your doctor about all medications you are taking, especially TKIs. A doctor's prescription is mandatory for this test.
Method: Venipuncture or bone marrow aspiration
Laboratory Analysis
A blood sample will be drawn from a vein in your arm, or a bone marrow aspiration may be performed by a specialist. The procedure is quick and generally well-tolerated.
Report Delivery
You can resume normal activities immediately. If bone marrow aspiration was performed, you may experience mild soreness at the site, which should resolve within a few days.
Timeline: Reports are typically available within 7-8 days after the sample is received by the laboratory.
Patient Instructions
About This Test
Who Should Get This Test
The primary purpose of BCR-ABL1 Kinase Domain Mutation Analysis is to identify mutations in the kinase domain of the BCR-ABL1 gene that confer resistance to tyrosine kinase inhibitors (TKIs). This information is essential for guiding treatment decisions in patients with CML or Philadelphia-positive ALL who exhibit suboptimal response or relapse. By pinpointing specific mutations, clinicians can choose the most effective TKI or consider alternative therapies such as ponatinib or allogeneic stem cell transplantation. Additionally, the test helps in monitoring disease progression and predicting prognosis. It is also used in research settings to understand resistance mechanisms. Overall, IRMA plays a pivotal role in personalized oncology, ensuring that patients receive the most appropriate and timely interventions.
How to Prepare
- Use EDTA vacutainer for blood sample
- Transport sample immediately to the laboratory at cool pack (2-8°C)
- Do not freeze the sample
- Label the sample with patient name, date, and time of collection
Doctor's Notes
Reviewed by Dr Pasupathy Arumugam — MBBS, MD (Pathology) · Reg. No. 21521
"BCR-ABL1 kinase domain mutations are a common cause of resistance to tyrosine kinase inhibitors (TKIs) in CML. Early detection allows for timely therapy adjustment, improving patient outcomes."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Clotted or hemolyzed sample
- Incorrect container (e.g., heparin tube)
- Sample not transported within 24 hours
- Insufficient sample volume
Understanding Your Results
No resistance mutations found; current TKI therapy is likely effective. Continue monitoring.
Resistance to imatinib, dasatinib, and nilotinib; consider ponatinib or alternative therapy.
Resistance to imatinib and nilotinib; dasatinib may be effective.
Resistance to dasatinib; imatinib or nilotinib may be effective.
Clinical significance varies; consult oncologist for personalized treatment.
Consult your oncologist if you experience symptoms such as persistent fatigue, unexplained weight loss, fever, easy bruising, or abdominal discomfort, especially if you are on TKI therapy. Also, if your BCR-ABL1 transcript levels are rising or if you have signs of disease progression, discuss the need for this test.
Limitations
- ⚠Sanger sequencing may not detect low-level mutations (<20% allele frequency)
- ⚠Only mutations in the kinase domain are detected; mutations outside this region are not covered
- ⚠Test does not quantify BCR-ABL1 transcript levels; separate quantitative PCR is needed for monitoring
- ⚠Results should be interpreted in conjunction with clinical and hematological findings
Risks & Considerations
- ●Minimal risk of bleeding or infection at the blood draw site
- ●Bone marrow aspiration carries a small risk of bleeding, infection, or discomfort
- ●No radiation exposure or other significant risks
Interfering Factors
- ●Inadequate sample volume or poor quality DNA
- ●Hemolysis or clotting of blood sample
- ●Delay in sample transport leading to DNA degradation
- ●Presence of maternal cells in bone marrow aspirate (rare)
- ●Prior allogeneic stem cell transplant may cause mixed chimerism
Compare With Similar Tests
| Test | BCR-ABL1 Kinase Domain Mutation Analysis [IRMA] | BCR-ABL1 Quantitative PCR | BCR-ABL1 Qualitative PCR | Cytogenetic Analysis (Karyotype) | FISH (Fluorescence In Situ Hybridization) |
|---|---|---|---|---|---|
| Comparison | BCR-ABL1 Kinase Domain Mutation Analysis [IRMA] |
Frequently Asked Questions
What is BCR-ABL1 Kinase Domain Mutation Analysis [IRMA]?
What is the cost of the test?
What sample is required?
Is fasting required?
How long does it take to get results?
What is the method used?
Who should get this test?
Can this test be done without a doctor's prescription?
Is home sample collection available?
What does a positive result mean?
Are there any risks associated with the test?
Is the test covered by insurance?
Related Tests
B-Cell Rearrangement Detection Test
₹22,000Acute Lymphoblastic Leukemia (ALL) Cytogenetics Panel Test
₹20,000Epstein-Barr Virus Early RNA (EBER-ISH) In-Situ-Hybridization Test
₹6,000OncoPro NCCN Lung Cancer Panel with PD-L1 Test
₹140,400Acute Myeloid Leukemia (AML) Cytogenetics Panel Test
₹23,000AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test
₹6,000Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.